Table 3.

Down-Regulation of Pol η Sensitizes Cells to Gemcitabine/Cisplatin Treatments

LC50 (with 2 nmol/L gemcitabine)GM637GM637-pol η siRNAXP30RO
Cisplatin (nmol/L)668 ± 20 (673 ± 45)214 ± 7 (175.4 ± 16)47 ± 3 (23.1 ± 4)
  • NOTE: Numbers in parentheses are mean ± SD from two independent experiments each conducted in duplicates of trypan blue exclusion assay.